We are live on
!
Find out more
VIA
Vident Investment Advisory Portfolio holdings
AUM
$2.9B
1-Year Est. Return
24.67%
This Fund
S&P 500
This Quarter
Est. Return
-0.3%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$752M
AUM Growth
+$253M
(+51%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
35.64%
Top 10 Holdings %
Top 10 Hldgs %
9.6%
Holding
1,082
New
405
Increased
619
Reduced
41
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
INP
iPath ETNs Linked to the MSCI India Total Return Index
INP
|
+$17.4M |
| 2 |
Apple
AAPL
|
+$7.52M |
| 3 |
Broadcom
AVGO
|
+$6.81M |
| 4 |
Bausch Health
BHC
|
+$5.93M |
| 5 |
NBIS
Nebius Group N.V.
NBIS
|
+$4.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$2.86M |
| 2 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$1.98M |
| 3 |
EGLE
Eagle Bulk Shipping Inc.
EGLE
|
+$1.84M |
| 4 |
ALTR
Altera Corp
ALTR
|
+$1.74M |
| 5 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$1.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.2% |
| 2 | Healthcare | 13.08% |
| 3 | Industrials | 11.83% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Quest Diagnostics
DGX
$26.3B
| $867K | 0.12% |
11,960
+949
| +9% | +$70.1K |
|
227
Avery Dennison
AVY
$13.4B
| $864K | 0.12% |
14,179
+1,653
| +13% | +$96.1K |
|
228
Kosmos Energy
KOS
$1.48B
| $858K | 0.11% |
101,763
+4,780
| +5% | +$42.5K |
|
229
McKesson
MCK
$101B
| $855K | 0.11% |
3,802
+262
| +7% | +$60.6K |
|
230
Haemonetics
HAE
$4B
| $852K | 0.11% |
20,611
+972
| +5% | +$41K |
|
231
Graham Holdings Company
GHC
$5.02B
| $849K | 0.11% |
1,307
+54
| +4% | +$34.2K |
|
|
OCR
232
DELISTED
OMNICARE INC
OCR
| $838K | 0.11% |
8,892
+422
| +5% | +$37.6K |
|
|
AET
233
DELISTED
Aetna Inc
AET
| $835K | 0.11% |
6,553
+539
| +9% | +$61.5K |
|
234
Consolidated Edison
ED
$39.9B
| $830K | 0.11% |
14,335
+1,721
| +14% | +$104K |
|
235
Sonoco
SON
$5.74B
| $830K | 0.11% |
19,374
+280
| +1% | +$12.6K |
|
236
Merck
MRK
$318B
| $829K | 0.11% |
15,269
+827
| +6% | +$46.4K |
|
237
ICF International
ICFI
$1.72B
| $826K | 0.11% |
23,705
+1,127
| +5% | +$42.4K |
|
|
JNPR
238
DELISTED
Juniper Networks
JNPR
| $822K | 0.11% |
31,667
+2,973
| +10% | +$78.1K |
|
|
DBD
239
DELISTED
Diebold Nixdorf Incorporated
DBD
| $817K | 0.11% |
23,357
+1,094
| +5% | +$38.6K |
|
240
Labcorp
LH
$25.9B
| $813K | 0.11% |
7,810
+678
| +10% | +$70.6K |
|
241
Insight Enterprises
NSIT
$4.38B
| $810K | 0.11% |
27,073
+1,243
| +5% | +$36.9K |
|
242
Smith & Wesson
SWBI
$637M
| $807K | 0.11% |
63,279
+3,532
| +6% | +$40.7K |
|
243
UnitedHealth
UNH
$370B
| $807K | 0.11% |
6,611
+553
| +9% | +$65.4K |
|
244
Integra LifeSciences
IART
$1.34B
| $804K | 0.11% |
29,201
+1,766
| +6% | +$47.1K |
|
|
POLY
245
DELISTED
Plantronics, Inc.
POLY
| $800K | 0.11% |
14,202
+677
| +5% | +$37.7K |
|
246
ABM Industries
ABM
$2.84B
| $798K | 0.11% |
24,273
+1,162
| +5% | +$37.7K |
|
247
HF Sinclair
DINO
$14.5B
| $798K | 0.11% |
18,691
+1,119
| +6% | +$45.2K |
|
248
Marathon Petroleum
MPC
$83.7B
| $796K | 0.11% |
15,213
+1,591
| +12% | +$81K |
|
249
American Eagle Outfitters
AEO
$3.01B
| $795K | 0.11% |
46,172
+2,207
| +5% | +$37.1K |
|
250
Cardinal Health
CAH
$55.4B
| $795K | 0.11% |
9,498
+779
| +9% | +$68.8K |
|
Similar funds
EST
TCM
AWS
WI
JP
VCM
FCB
FCFS
Vident Investment Advisory's Q2 2015 Portfolio in Review
As of Q2 2015, Vident Investment Advisory held 1,082 positions worth $752M, up 51% from $498M the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
Vident Investment Advisory deployed $268M of net new capital in Q2 2015, opening 405 new positions and adding to 619 existing holdings. Its largest new stake was iPath ETNs Linked to the MSCI India Total Return Index: 244,802 shares worth $17.2M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $2.86M trimmed.
- Vident Investment Advisory's largest Q2 2015 buy was iPath ETNs Linked to the MSCI India Total Return Index: 244,802 shares worth $17.2M.
- Vident Investment Advisory added most to Apple in Q2 2015, an estimated $7.52M increase.
- Vident Investment Advisory's biggest Q2 2015 reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, cutting an estimated $2.86M.
- Vident Investment Advisory fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $1.98M.
- Vident Investment Advisory's ten largest holdings make up 9.6% of its $752M portfolio in Q2 2015.
- Vident Investment Advisory opened 405 new positions and closed 17 in Q2 2015.
- Vident Investment Advisory's portfolio value rose 51% quarter-over-quarter to $752M.
Based on Vident Investment Advisory's 13F filing for Q2 2015, filed 29 Jul 2015.